Pharmaceuticals company Shree Ganesh Remedies announced Q3FY25 results Revenue from Operations: Rs 27.05 crore compared to Rs 27.97 crore during Q3FY24, change -3%. EBITDA: Rs 9.90 crore compared to Rs 8.21 crore during Q3FY24, change 21%. EBITDA margin: 36.6% for Q3FY25. PBT: Rs 7.54 crore compared to Rs 7.42 crore during Q3FY24, change 2%. PAT: Rs 5.43 crore compared to Rs 4.82 crore during Q3FY24, change 13%. EPS: Rs 4.23 for Q3FY25. Gunjan Kothia, Promoter, Whole-Time Director, said: I am pleased to share our performance update for Q3FY25. In this quarter, we experienced a decline in revenue due to intensified domestic competition for our traditional products, which led to price reductions and impacted profitability. However, it is noteworthy that we achieved robust growth in volumes during this period. The decline in profitability from traditional products was effectively offset by the high margins generated from our CRAMS projects, as previously guided. On the operational front, the ramp-up of Block 8 is progressing according to plan, and we anticipate reaching optimal capacity utilisation by early next financial year. Leveraging this steady ramp-up, we have decided to undertake a maintenance and refurbishment shutdown of Block 3 during the current quarter. While this shutdown means we do not foresee volumetric growth for this quarter, we are wellpositioned to manage the volume decline from Block 3 with the increased output from Block 8. Furthermore, I am pleased to announce that the designing phase of Block 7 has been completed, and construction activities have commenced. We expect to complete this new block by the end of Q4FY26 and initiate commercial production in Q1FY27. Additionally, recognising the strong opportunities ahead, we are intensifying our R&D; efforts by adding an R&D; block at our existing site. The design work is currently underway, and construction will begin shortly. A significant highlight of this quarter is our recent Memorandum of Understanding (MOU) with a leading Japanese company. This Long-Term Strategic Supply Agreement marks a pivotal step in our strategic contract manufacturing venture within the specialty chemicals market. Under this agreement, we will manufacture three innovative products that will be introduced as the first of their kind in India. This partnership not only showcases our capabilities but also positions us to meet growing international market demands effectively. Result PDF